Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Parenchyma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Liver Parenchyma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000270-28 Sponsor Protocol Number: NL75171.058.20 Start Date*: 2022-06-30
    Sponsor Name:Leiden University Medical Center
    Full Title: Selective Indocyanine Green Injection of a Segmental Hepatic Artery Followed by Near-Infrared Fluorescence Guided Anatomical Liver Resection: A Feasibility Study
    Medical condition: Hepatocellular carcinoma, hepatic adenoma, intrahepatic cholangiocarcinoma, colorectal liver metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000711-26 Sponsor Protocol Number: IOM-114 Start Date*: 2004-12-22
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: ABDOMINAL COMPUTED TOMOGRAPHY: IOMERON®400 VS VISIPAQUE™320 ENHANCEMENT (ACTIVE).
    Medical condition: subjects with mild to moderate renal impairment scheduled to undergo clinically-indicated IV contrast –enhanced MDCT scanning of the liver
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004176-21 Sponsor Protocol Number: CMC-P005 Start Date*: 2007-10-01
    Sponsor Name:CMC Contrast AB c/o Öresund Health Care Management
    Full Title: Evaluation of the diagnostic efficacy of CMC-001 (MnCl2 tetrahydrate) in MR cholangiography in patients with suspected liver lesions. A randomised, parallel group, open-label Phase II trial.
    Medical condition: Liver lesions. CMC-001 is an orally administered contrast medium containing manganese (Mn) as the active imaging substance. Manganese is absorbed by the healthy parts of the liver and will thus cre...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002985-70 Sponsor Protocol Number: MD-R20080507 Start Date*: 2009-04-23
    Sponsor Name:University of Magdeburg
    Full Title: Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.
    Medical condition: Irradiation damage to the liver after HDR-brachytherapy of liver metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003741-42 Sponsor Protocol Number: 31031981 Start Date*: 2014-05-06
    Sponsor Name:Medizinische Universität Innsbruck, Abteilung für Nuklearmedizin
    Full Title: PROSPECTIVE STUDY OF [68GA]NODAGA-RGD-PET FOR THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA AND THE ASSESSMENT OF TREATMENT RESPONSE
    Medical condition: This trial investigates a new tracer substance for PET scan of hepatocellular carcinoma in patients with liver disease. The condition investigated is a hepatocellular carcinoma in patients with liv...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004505-29 Sponsor Protocol Number: 2676 Start Date*: 2008-05-15
    Sponsor Name:Royal Marsden NHS Trust
    Full Title: Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer
    Medical condition: Metastatic colorectal adenocarcinoma with metastases involving the liver only
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004515-56 Sponsor Protocol Number: hepatology_MT_2007-08 Start Date*: 2008-04-28
    Sponsor Name:Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG
    Full Title: Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002105-44 Sponsor Protocol Number: ML20982 Start Date*: 2008-07-02
    Sponsor Name:Military Medical Academy Hospital for Active Treatment, Sofia
    Full Title: Open – label, non randomized clinical study of Neoadjuvant chemotherapy with FOLFIRI and Avastin in patients with non-resectable liver metastases of colorectal cancer
    Medical condition: Metastatic (liver metastases) colorectal cancer, with no prior chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024700 Liver metastases LLT
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002105-22 Sponsor Protocol Number: EVL-VHC-HVH.12 Start Date*: 2012-08-17
    Sponsor Name:Dra Itxarone Bilbao. Servicio de cirugía hepatobiliopancreatica y trasplantes. HUVH
    Full Title: Personal monitoring of liver transplant patients infected with Hepatitis C Virus. Pilot study to compare the evolution of Hepatitis C by receiving immunosuppression with tacrolimus in combination w...
    Medical condition: Recurrence of hepatitis C post-liver transplantation in patients with hepatitic C.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10070678 Hepatitis C recurrent LLT
    14.1 10042613 - Surgical and medical procedures 10024716 Liver transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002393-12 Sponsor Protocol Number: PRODIGE49 Start Date*: 2020-10-05
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first-line treatment of metastatic colorectal cancer restricted to the liver
    Medical condition: colorectal cancer with hepatic metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000144-18 Sponsor Protocol Number: CDKO-125a-010 Start Date*: 2017-08-01
    Sponsor Name:Tiziana Life Sciences Plc
    Full Title: Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients with Unresectable or Metastatic Hepatocellular Carcinoma
    Medical condition: Uunresectable or metastatic hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000028-33 Sponsor Protocol Number: D-FR-01070-003 Start Date*: 2018-07-17
    Sponsor Name:Ipsen Pharma
    Full Title: A non-randomised, phase II study to evaluate the optimal uptake time of 68Ga-OPS202 as a sstr2 positive PET imaging agent in subjects with newly diagnosed breast cancer. (Sub-study of Master Protoc...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004088-77 Sponsor Protocol Number: BA2006/03/03 Start Date*: 2007-12-03
    Sponsor Name:BioAlliance Pharma
    Full Title: Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.
    Medical condition: Advanced hepatocarcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000417-44 Sponsor Protocol Number: PHP-OCM-301A Start Date*: 2016-03-31
    Sponsor Name:Delcath Systems, Inc
    Full Title: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma.
    Medical condition: Hepatic-Dominant Ocular Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068117 Metastatic ocular melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003669-17 Sponsor Protocol Number: NEOPA Start Date*: 2013-12-17
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).
    Medical condition: Non-metastasized, adenocarcinoma of the pancreatic head/uncinate process or body of pancreas that was treated with extended pancreatic head/body resection larger than 2 cm in size (≥cT2) and/or in ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001364-22 Sponsor Protocol Number: ML25625 Start Date*: 2011-05-25
    Sponsor Name:ROCHE
    Full Title: A multi-center, open-label clinical trial to evaluate the objective response rate of bevacizumab in combination with modified FOLFOX-6 followed by one year of maintenance with bevacizumab alone in ...
    Medical condition: Metastatic colorectal cancer: histologically confirmed adenocarcinoma of the colon or rectum and metastatic disease confined to the liver (with initially not or borderline resectable liver metastas...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000499-83 Sponsor Protocol Number: 1386.4 Start Date*: 2017-05-04
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orall...
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10076331 Steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) IE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003484-45 Sponsor Protocol Number: 2007/3 Start Date*: 2007-05-25
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTA...
    Medical condition: UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029104 SOC
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004248-49 Sponsor Protocol Number: NL69508.058.19 Start Date*: 2020-02-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma (CHOPIN)
    Medical condition: Metastatic uveal melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA